Emily Prendergast - Concepedia

Author

Emily Prendergast

Minnesota Oncology ORCID

Also Known As

E Prendergast, E. Prendergast, E.N. Prendergast, Emily N Prendergast, Emily N. Prendergast, Emily Prendergast

Publications

825

Citations

H-Index

Concepts

All Affiliations

Minnesota Oncology Cedars-Sinai Medical Center The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute University of California, Los Angeles University of Arizona

About

Emily Prendergast is an author at Minnesota Oncology specializing in medicine, obstetrics, and gynecology oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	330
2	Health Sciences	1	1	39
3	Natural Sciences	1	1	53
4	Public Health	1	1	18
5	Biology	1	1	53

Emily Prendergast

Publications

719

Citations

H-Index

Page 1

	Year	Citations
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45) Bradley J. Monk, Christine Parkinson, Myong Cheol Lim, Journal of Clinical Oncology	2022	346
Evaluation of venous thrombosis and tissue factor in epithelial ovarian cancer Joshua G. Cohen, Emily Prendergast, Julia E. Geddings, Gynecologic Oncology Tumoral PathologyVenous ThrombosisEpithelial Ovarian CancerMedicinePathology	2017	56
Optimizing exosomal RNA isolation for RNA-Seq analyses of archival sera specimens Emily Prendergast, Marcos Abraão de Souza Fonseca, Felipe Segato Dezem, PLoS ONE GeneticsExosomal Rna IsolationPathologyExtracellular MicrovesiclesGenomics	2018	53
Discovery of novel stroke-responsive lncRNAs in the mouse cortex using genome-wide RNA-seq Sunil Bhattarai, Fabrizio Pontarelli, Emily Prendergast, Neurobiology of Disease NeurogenomicsNovel Stroke-responsive LncrnasMedicineRna BiologyLong Non-coding Rna	2017	51
Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapy Emily Prendergast, Laura L. Holman, Annie Y. Liu, Gynecologic Oncology Tumor HeterogeneityComprehensive Genomic ProfilingMedicineGynecologyCancer Genomics	2019	39
Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma – A multi-institutional cohort Emily Prendergast, Marie Holzapfel, Jennifer J. Mueller, Gynecologic Oncology Versus SixMedicineCancer ManagementGynecologyCancer Treatment	2016	36
Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC). Susana Banerjee, Kari L. Ring, Els Van Nieuwenhuysen, Journal of Clinical Oncology Cancer ManagementGynecologyPharmacotherapyGynecology OncologyTumor Biology	2023	34
Evaluation of an individualized starting-dose of niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study. Mansoor Raza Mirza, Antonio González-Martı́n, Whitney A. Spannuth Graybill, Journal of Clinical Oncology Cancer ManagementRecurrent Ovarian CancerPharmacotherapyNiraparib ArmIndividualized Starting Dose	2020	23
Doubling down on the future of gynecologic oncology: The SGO future of the profession summit report Stephanie V. Blank, Warner K. Huh, Maria C. Bell, Gynecologic Oncology Sgo FutureMedicineCancer ManagementGynecologyProfession Summit Report	2023	20
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT‐OV26/GOG‐3012 trial Mansoor Raza Mirza, Antonio González-Martı́n, Whitney A. Spannuth Graybill, Cancer	2023	20

Page 1